×
IBio Total Liabilities 2010-2024 | IBIO
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
IBio total liabilities from 2010 to 2024. Total liabilities can be defined as the total value of all possible claims against the corporation.
View More
IBio Total Liabilities 2010-2024 | IBIO
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
IBio total liabilities from 2010 to 2024. Total liabilities can be defined as the total value of all possible claims against the corporation.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$159.1B
Vertex Pharmaceuticals (VRTX)
$124.6B
Bristol Myers Squibb (BMY)
$118.6B
Gilead Sciences (GILD)
$114.8B
CSL (CSLLY)
$88.8B
Regeneron Pharmaceuticals (REGN)
$86B
GSK (GSK)
$71.3B
Argenex SE (ARGX)
$35.6B
Alnylam Pharmaceuticals (ALNY)
$33.3B
BioNTech SE (BNTX)
$24.8B
Biogen (BIIB)
$24B
Illumina (ILMN)
$22.6B
BeiGene (BGNE)
$18.8B
Moderna (MRNA)
$15.3B
Incyte (INCY)
$15B
Genmab (GMAB)
$14B
Insmed (INSM)
$12.7B
BioMarin Pharmaceutical (BMRN)
$12.5B
Vaxcyte (PCVX)
$11.6B
Bio-Techne Corp (TECH)
$11.5B
Sarepta Therapeutics (SRPT)
$10.4B
Exelixis (EXEL)
$10B
Revolution Medicines (RVMD)
$9.7B
QIAGEN (QGEN)
$9.6B
Exact Sciences (EXAS)
$9.4B
Bio-Rad Laboratories (BIO.B)
$9.4B
Intra-Cellular Therapies (ITCI)
$9.3B
Roivant Sciences (ROIV)
$8.6B
Repligen (RGEN)
$8B
Ascendis Pharma (ASND)
$7.5B